Info

GTC Biotherapeutics, Inc. is engaged in the development and production of human therapeutic proteins through transgenic technology that enables animals to produce a recombinant form of a specified human protein in their milk. Using this technology, the Company is developing a portfolio of recombinant blood proteins to treat a range of genetic and acquired blood deficiencies, including hemophilia and other blood coagulation disorders. It has also initiated the development of a portfolio of monoclonal antibodies (MAb’s), for use as potential follow-on biologics targeted at several market products. Its first product ATryn, its recombinant form of human antithrombin, validated its transgenic production technology’s capability. In February 2008, it announced that ATryn had met the statistical requirements for the primary endpoint in its trial to support its filing of a Biologics License Application (BLA), for the use of ATryn in United States.(Source: 10-K)